VCYT Comptes : Analyse IA Veracyte Inc

Accueil

Stock

VCYT

VCYT Financier

Veracyte Inc

$35.77

1.76%

$0.62

À la fermeture : Feb 13, 16:00:00 GMT-5

$35.77

Post-Marché: Feb 13, 20:00:00 GMT-5

Aperçu Prévision Gagner Dividendes Comptes financiers

Revenus

État de situation

Flux de trésorerie

Annuel

Trimestriellement

VCYT Revenu

Chiffres en millions de dollars américains. L'exercice financier va de février à janvier.

Breakdown	TTM	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020
Revenus	495	445	361	296	219	117
Croissance des revenus (H/H)	16%	23%	22%	35%	87%	-3%
Coût des ventes	155	147	112	101	74	41
Bénéfice brut	339	298	248	195	145	76
Vente, Général et Administration	215	201	184	168	134	87
Recherche et développement	67	68	56	40	29	17
Frais d'exploitation	290	278	265	232	204	111
Autres revenus (charges) non opérationnels	-7	0	1	2	1	0
Bénéfice avant impôts	31	25	-76	-36	-81	-34
Charge d'impôt sur le revenu	0	1	-2	0	-6	--
Bénéfice net	30	24	-74	-36	-75	-34
Croissance du bénéfice net	-433%	-132%	106%	-52%	121%	183%
Actions en circulation (diluées)	79.69	78.16	72.64	71.5	67.9	53.2
Variation des actions (H-H)	2%	8%	2%	5%	28%	15%
EPS (dilué)	0.37	0.3	-1.02	-0.51	-1.11	-0.66
Croissance du EPS	-413%	-130%	101%	-54%	68%	144%
Flux de trésorerie libre	97	63	34	-1	-37	-12
Flux de trésorerie libre par action	--	--	--	--	--	--
Marge brute	68.48%	66.96%	68.69%	65.87%	66.21%	64.95%
Marge opérationnelle	9.69%	4.26%	-4.7%	-12.5%	-26.94%	-29.91%
Marge bénéficiaire	6.06%	5.39%	-20.49%	-12.16%	-34.24%	-29.05%
Marge du flux de trésorerie libre	19.59%	14.15%	9.41%	-0.33%	-16.89%	-10.25%
EBITDA	70	42	10	-12	-40	-28
Marge EBITDA	14.14%	9.43%	2.77%	-4.05%	-18.26%	-23.93%
D&A pour le résultat opérationnel	22	23	27	25	19	7
EBIT	48	19	-17	-37	-59	-35
Marge EBIT	9.69%	4.26%	-4.7%	-12.5%	-26.94%	-29.91%
Taux d'imposition effectif	0%	4%	2.63%	0%	7.4%	--

Statistiques clés

Clôture préc.

$35.15

Prix d'ouverture

$35.17

Plage de la journée

$35.17 - $36.53

Plage de 52 semaines

$22.61 - $50.71

Volume

577.7K

Volume moyen

842.2K

BPA (TTM)

0.38

Rendement en dividend

Capitalisation boursière

$2.8B

Qu’est-ce que VCYT ?

Veracyte, Inc. engages in the research, development and commercialization of diagnostic products. The company is headquartered in South San Francisco, California and currently employs 824 full-time employees. The company went IPO on 2013-10-30. The firm enables clinicians with insights they need to guide and help patients to diagnose and treat cancer. The Veracyte Diagnostics Platform delivers cancer tests that are fueled by broad genomic and clinical data, deep bioinformatic and AI capabilities, and an evidence-generation engine, which drives durable reimbursement and guideline inclusion for its tests, along with new insights to support continued innovation and pipeline development. The firm offers tests for prostate cancer (Decipher Prostate), thyroid cancer (Afirma), breast cancer (Prosigna) and bladder cancer (Decipher Bladder). The company has developed the noninvasive Percepta Nasal Swab test to help physicians accurately and quickly determine lung cancer risk. All of its tests are serviced through its own Clinical Laboratory Improvement Amendments (CLIA) certified laboratories in South San Francisco, California, San Diego, California and Austin, Texas.



Fonctionnalités

Copilote IA pour actions et cryptomonnaies

Prédiction des prix

Suivi des collectes de fonds

Thèmes

Comparaison de cryptomonnaies

Ressources